Setting -Official death certifications from the World Health Organization database. Main results -In the 1950s, the highest age adjusted (on the world standard population) mortality rates for BPH in Europe were in Denmark (22-81100000) and Germany (18-1), followed by Scandinavian countries, the UK, and Switzerland. Italy had rates around 10,100 000, and rates were lower in eastern and southern Europe (5-8/ 100 000). Between 1950 and 1990, a fall of over 90%, or even 95%, was observed in most western European countries. Thus, in the early 1980s, overall mortality from BPH ranged between 0 5 and 1 5I100 000 in most western European countries. In proportional terms, similar reductions were registered in other developed countries ofNorth America, Asia (that is, Japan or Singapore), and Oceania. A fall in rates was also observed in eastern Europe and in Latin America, particularly from the late 1970s onwards, although these reductions were generally much smaller. Thus, in the early 1990s, most countries in these areas had BPH rates between 1 and 51100 000. The pattern of trends was, at least qualitatively, similar at younger ages, although most falls were proportionally greater.
Conclusions -The most probable interpretation of these trends is that therapeutic improvements -including more widespread and timely surgery, introduction of less invasive techniques, such as transurethral prostatectomy, and possibly the development ofmedical treat- Benign prostatic hyperplasia (BPH) is a common condition in elderly men. While it is almost absent below age 45 years, its pathological prevalence is around 30% at age 50, and over 50% above age 70. 12 The clinical prevalence of symptoms is much lower, however, and has been estimated at around a half to a third of the pathological one. 3 Certified mortality data on BPH over the past few decades may have been influenced by substantial changes in both the certification and treatment of the disease. Improved diagnosis would, at least in principle, have introduced spurious trends in BPH rates. Improved treatment -including surgical advancements such as transurethral prostatectomy, with its subsequent developments, and new drug therapies -should, however, have reduced mortality from the disease."
There are substantial temporal variations in the adoption of any such procedure in various countries and areas of the world.57 1>I2 To provide a systematic overview oftrends in mortality from BPH over the past few decades, we systematically analysed data from 41 countries available through the World Health Organization (WHO) mortality database. This overview has potential therefore to allow priorities to be defined for intervention on a clinical and public health level. Figure 2 .
Methods

EUROPE
In the 1950s, the highest age standardised mor- Total, all ages tality rates from BPH were in Denmark (22 9/ 100000) and Germany (18 1), followed by Norway (17 6) , the UK (15 to 18), Switzerland (16 0), The Netherlands (15 3) , other Scandinavian countries ( 1 2-1 3) , and Austria (12 2). Italy had rates around 10/100 000, while those in eastern Europe, Belgium, France, Spain, Portugal and Greece were lower (between 5 and 9/100 000). Inspection of the age specific rates indicates that there were substantial differences between various countries across subsequent age groups, although these were often and apparently larger at elderly ages. Still, a noticeable heterogeneity of BPH rates was evident even at younger ages. For instance, BPH mortality rates in 1950-54 for the age group 45 to 64 years were 7-4 in Denmark and 5 9 in Germany, but only 1 8/100 000 in France.
Over the four decades considered, there were steady and substantial downward trends in BPH mortality in all western European countries. In the late 1980s or early 1990s, overall mortality ranged between 0-5 and 0 9/100 000 in France, Belgium, Germany, Greece or Portugal, and 1 2) . In addition, the decline in Eastern Europe was somewhat larger at a younger age.
AMERICAS
Mortality from BPH in the early 1950s in Canada and the United States was relatively low (7-8 4/100 000). Moreover, in both countries a substantial and steady decline was observed over the past few decades. Thus, in 1985-89, the age standardised mortality rates were 0-38/100 000 males in Canada, and 0-24 in the USA -two of the lowest rates in the world. In both countries, the fall in rates was substantial in all subsequent age groups, including the elderly one. The decline was appreciable also in Puerto Rico and Argentina, whose rates were 0 2 and 0-4/100 000 in the late 1980s. BPH death rates in the 1950s were also comparatively low in most other American countries that provided data for the WHO dataset, but the falls in rates were appreciably smaller. The declines in the overall age standardised rates were from 8 4 to 3-4 in Chile, [7] [8] [9] to 2 8 in Costa Rica, 2-1 to 1 9 in Mexico, 8- Although more widespread and timely surgery seems to have had a major impact on BPH rates worldwide, whether the persisting wide variation in prostatectomy rates in various developed countries has had any substantial impact on BPH mortality is still debatable.'0 These uncertainties and any other limitation of the data notwithstanding, the results of this study clearly indicate that there are areas of the world -including several countries of eastern Europe and South America -where the management of BPH is far from optimal, and where death rates from such an avoidable disease are still high. In these areas, the introduction of modern management techniques would be important on a public health scale.
